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Abstract. Amyotrophic lateral sclerosis (ALS) is a progres‑
sive neurodegenerative disease. Through a genome‑wide
association study (GWAS), the Sec1 family domain‑containing
protein 1 (SCFD1) rs10139154 variant at 14q12 has emerged as
a risk factor gene for ALS. Moreover, it has been reported to
influence the age at onset (AAO) of patients with ALS. The
aim of the present study was to assess the association of the
SCFD1 rs10139154 polymorphism with the risk of developing
ALS. For this purpose, 155 patients with sporadic ALS and 155
healthy controls were genotyped for the SCFD1 rs10139154.
The effect of the SCFD1 rs10139154 polymorphism was
then examined on the following parameters: i) The risk of
developing ALS; ii) the AAO of ALS; iii) the site of ALS
onset (patients with bulbar onset ALS vs. healthy controls;
and patients with limb onset ALS vs. healthy controls); and
iv) the AAO of ALS onset with subgroup analyses based on
the site of onset (bulbar and limb, crude and adjusted for sex).
The analysis of all the outcomes was performed assuming five
genetic models. Crude and adjusted analyses were applied. The
threshold for statistical significance was set at 0.05. The results
revealed no association between SCFD1 rs10139154 and any of
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the examined phenotypes in any of the models examined. On
the whole, based on the findings of the present study, SCFD1
rs10139154 does not appear to play a determining role in the
risk of developing ALS.
Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative
disease of a yet undetermined etiology, and it is estimated
to be the most common type of motor neuron disease during
adulthood (1). A great variation has been observed in terms
of the frequency of ALS between different countries, with
males exhibiting a slightly elevated risk of developing ALS
compared with females, particularly as regards the form of
ALS with limb onset (2‑4). On the other hand, there is a slight
female predominance in bulbar onset ALS (2‑4).
ALS can be phenotypically manifested with symp‑
tomatology from the upper (e.g., spasticity, weakness,
hyperreflexia and pseudobulbar palsy) and lower (e.g. atrophy
of muscles, fasciculations, hyporeflexia and muscle cramps)
motor neurons (5). The consequent progressive and irrevers‑
ible muscular weakness and atrophy, leads to the paralysis of
respiratory muscles and respiratory failure (6). Apart from
motor deficits, non‑motor symptoms [e.g., frontotemporal
dementia (FTD)] can also develop with ALS (7). The associa‑
tion between ALS and FTD is evident through the crosstalk
that exists between them clinically, genetically and neuro‑
pathologically (8).
From a neuropathological aspect, ALS presents as a
degeneration of motor neurons, while intraneuronal inclusions
in glial cells and neurons can also be observed (9). While
the etiology and the exact mechanisms that possible lead to
the development of ALS remain to be determined, a notable
amount of research suggests that complex mechanisms,
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that interact with each other, are possibly implicated in the
development of ALS (9,10). Mitochondrial dysfunction,
inflammatory abnormalities, pathological protein aggregation,
defective microtubule function, inadequate RNA activity,
oxidative stress and glutamate excitotoxicity, to mention
a few, are among the pathological processes that have been
found to confer susceptibility to ALS (11,12).
The molecular pathways through which the aforementioned
mechanisms can lead to ALS are far from being completely
elucidated (13). However, there are a number of indications that
genetic, environmental and epigenetic factors all contribute to
ALS susceptibility (14). Among the exogenous factors, head
trauma, smoking, viral infections, exposure to pesticides and
heavy metals, antioxidants, physical exercise, exposure to
electromagnetic fields and body mass index have been previ‑
ously reported as possible triggers for the development of
ALS (15,16).
The contribution of genetic factors to ALS is supported
from robust data (17). Firstly, there is familial ALS (fALS;
accounting for almost 5‑10% of all ALS cases), where muta‑
tions >30 genes are considered as ALS causative ones (10,18).
Namely, mutations in the chromosome 9 open reading
frame 72 (C9orf72), superoxide dismutase type 1 (SOD1), TAR
DNA‑binding protein 43 (TDP‑43) and fused in sarcoma/trans‑
located in liposarcoma (FUS/TLS) genes are estimated to be
the commonest ones (10,18). Mutations in these genes can
lead to ALS; however, there are some genotype‑phenotype
associations, where patients with ALS carrying specific
mutations may exhibit specific sub‑phenotypes (19). For
example, C9orf72 can lead to ALS, behavioral variant FTD,
or ALS‑FTD, while mutations in the TDP43 gene can lead
to ALS with either bulbar or limb onset (19). Moreover, the
remaining 85‑90% of all ALS cases are considered as sporadic
ALS (sALS) (5), where a large amount of genetic loci have
been reported to modify the risk of developing ALS (20). At
this point, it is worth mentioning that the conferred risk from
rare genetic variants suggests an oligogenic disease pattern
concerning the ALS architecture (21,22).
The Sec1 family domain containing 1 (SCFD1) protein,
belongs to the Senc1/Munk 18 (SM) family of proteins (23).
These proteins are vesicle‑trafficking proteins, working
closely with a particular type of SNARE proteins, the
syntaxins (24,25). SCFD1 is implicated in a number of func‑
tions, such as cellular membrane fusion, oxidative‑stress,
intra‑Golgi‑retrograde transport and apoptosis (23‑26).
In 2016, a genome‑wide association study (GWAS) identi‑
fied the SCFD1 rs10139154 variant at 14q12 as a genetic locus
associated with ALS in the discovery phase; however, statis‑
tical significance was not found in the replication phase (27).
Moreover, recently, Chen et al (28) examined the effect of the
SCFD1 rs10139154 on a large Chinese population with ALS.
Based on the results of that study, the SCFD1 rs10139154 poly‑
morphism was shown to be associated with the age at onset
(AAO) of patients with ALS.
Taking into consideration that SCFD1 is involved in
mechanisms (23‑26) that are also possibly implicated in ALS
pathogenesis (e.g., oxidative stress and apoptosis) (11,12),
and that the studies examining the role of the SCFD1
rs10139154 variant regarding ALS have yielded inconsistent
results (27,28), the present case‑control study was conducted

with the aim of determining any possible association between
the SCFD1 rs10139154 variant and ALS. A Southeastern
European Caucasian (SEC) cohort (Greek) was analyzed,
primary aiming at detecting any association between SCFD1
rs10139154 and ALS. The present study also wished to
examine the effect of this polymorphism on several other ALS
endophenotypes.
Patients and methods
Study participants. In the current protocol, a total of 310
participants were drafted. In greater detail, 155 patients with
sporadic ALS, as well as 155 healthy controls were included.
The participants were recruited between March, 2017 and
September, 2017 from the University Hospital of Larissa
(Department of Neurology), in Larissa, Greece. Consultant
neurologists made the diagnoses of ALS, following the
El Escorial criteria (29). The inclusion criteria for the
participants with ALS were as follows: i) An age >18 years;
ii) Greek ethnicity; and iii) a diagnosis of ALS based on
the El Escorial criteria. The respective inclusion criteria for
healthy controls were the following: i) An age >18 years;
ii) of Greek ethnic origin; and iii) no referred family or
personal history of ALS or other neurological disorders.
The characteristics of the ALS cohort have been previ‑
ously described (30‑33). The research study protocol of the
present study was approved by the Local Ethics Committee
(University Hospital of Larissa: 59295/23‑01‑2017) and it
was deemed in accordance to the Declaration of Helsinki.
The experimental protocol was explained and all the partici‑
pants provided their written informed consent in order to be
included in the study, with the freedom of withdrawing from
the study at any given time.
Molecular genetics. The salting out method was used to
isolate genomic DNA from leucocytes (blood was collected
with peripheral venipuncture from each participant), a method
which has also been previously described (34,35). All the
samples derived from the healthy volunteers and the patients
with ALS were genotyped for the SCFD1 rs10139154 variant.
The method which was applied for genotyping was the TaqMan
allele specific discrimination assay on an ABI PRISM 7900
Sequence Detection System. The results were then analyzed
using SDS software (SDS 2.4). (Applied Biosystems; Thermo
Fisher Scientific, Inc.). In brief, this method consisted of an
initial enzyme activation occurring as the first step of PCR at
a 50˚C incubation for 2 min, followed by enzyme activation
at 95˚C for 10 min (one cycle), denaturation at 95˚C for 15 sec
and annealing/extension at 60˚C for 1 min (40 cycles for the
last two points). The personnel who performed the genotyping
was blinded to status of the samples.
Quality assessment. In order for the genotyping reproducibility
be evaluated, a random 10% of the sample was re‑genotyped,
with 100% concordance. Moreover, the threshold for the geno‑
type call rate (percentage of successfully genotyped samples)
was set as ≥95%. Additionally, the deviation or not from the
Hardy‑Weinberg equilibrium (HWE) was calculated with
the Chi‑squared test (36), in both the patients with ALS and
the healthy controls.
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Statistical analysis. The CaTS Power Calculator for Genetic
Studies (Center for Statistical Genetics, University of Michigan,
Ann Arbor, MI, USA) was used for the statistical power of
the current sample to be measured. With odds ratios (ORs)
along with the respective 95% confidence intervals (CIs), the
study sample was examined for associations between SCFD1
rs10139154 and ALS using SNPStats software (https://www.
snpstats.net/) (36). Towards this, five genetic models were
assumed: i) The co‑dominant model, where a P‑value with 2
degrees of freedom and 2 ORs were calculated [OR1: (mt/wt
vs. wt/wt) and OR2: (mt/mt vs. wt/wt)]; ii) the dominant model
(mt/mt + mt/wt vs. wt/wt); iii) the recessive model (mt/mt
vs. mt/wt + wt/wt); iv) the overdominant model (mt/wt vs.
mt/mt + wt/wt) and v) the log‑additive model, where mt/mt
carriers have a double risk of disease compared with mt/wt,
with wt/wt as a reference. In the analyses, the ‘C’ was defined
as the wild‑type allele (wt) and the ‘T’ as the mutant allele
(mt), for the SCFD1 rs10139154 variant. A P‑value <0.05 was
considered to indicate a statistically significant difference.
Both univariate (unadjusted) and multivariate (adjusted for age
and sex) analyses were performed.
The primary outcome of the protocol of the present study
was to examine the possible association between ALS and
SCFD1 rs10139154 (ALS vs. healthy controls). Unadjusted and
adjusted for age and sex analyses were performed. In addition,
the effects of SCFD1 rs10139154 on the following parameters
were examined: i) The AAO of ALS (unadjusted and adjusted
for sex); ii) the site of ALS onset (patients with bulbar onset
ALS vs. healthy controls; and patients with limb onset ALS vs.
healthy controls; unadjusted and adjusted for age and sex); and
iii) the AAO of ALS with subgroup analyses on the basis of
the site of onset (bulbar and limb, crude and adjusted for sex).
The analysis of all the outcomes was performed on the basis of
the aforementioned genetic models.
Results
A total of 310 individuals were recruited in the present
study; 155 patients with definite ALS [77 (49.7%) female,
age (mean ± standard deviation), 63.74±11.30 years], and
155 healthy volunteers (control group) matched for age and
sex. Approximately 7 out of 10 (67.1%) patients with ALS
confirmed a history of alcohol consumption, while 68.4% had
a history of smoking. The most common site of ALS onset
was the lower limbs (34.8%) and the bulbar type (32.3%). The
characteristics of the patients with ALS have been formerly
reported (30‑32).
The genotype call rate was 98.06% (304/310). Furthermore,
no deviation from the HWE was observed in both patients with
ALS and the healthy controls (P=0.37 and P=0.23, respec‑
tively) (Table I). The analysis for the power of the sample
size of the study was 80.4 to detect a significant association
(P<0.05) between ALS and SCFD1 rs10139154, with the
frequency of the minor T allele set at 37%, an ALS prevalence
of 5/100,000, and an approximate relative risk of 1.59 for the
multiplicative mode of inheritance.
The frequency of the minor allele (T) was 35 and 38% for
the patients with ALS and healthy controls respectively. The
genotypic frequencies C/C, C/T and T/T for the patients with
ALS, were 44, 42 and 14%, respectively, while in the group of
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Table I. Results from the Chi‑squared exact test for HWE for
the SCFD1 rs10139154 in healthy controls and in ALS cases.
P‑value

SNP
rs10139154

‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑

Healthy controls	ALS
0.23

0.37

HWE, Hardy‑Weinberg equilibrium; SNP, single nucleotide poly‑
morphism; ALS, amyotrophic lateral sclerosis; SCFD1, Sec1 family
domain containing 1.

healthy volunteers, the corresponding frequencies were 41, 42
and 17%, respectively. The allelic and genotypic frequencies
for SCFD1 rs10139154, for both patients with ALS and the
healthy controls are presented in Table II. The allele and geno‑
type numbers for SCFD1 rs10139154 in the healthy controls
and ALS cases are graphically presented in Figs. 1 and 2,
respectively.
Based on the univariate (unadjusted) and multivariate
(adjusted for age and sex) analyses, no significant association
was found between the SCFD1 rs10139154 polymorphism and
ALS in any genetic model examined (Table III). Subgroup
analysis (unadjusted and adjusted for age and sex) according
to the site of ALS onset (limb, bulbar) also did not reveal any
significant association (Table IV).
Furthermore, the analyses based on the AAO of ALS
(unadjusted and adjusted for sex), failed to produce any
statistically significant differences. The analyses for the AAO
of ALS with regards to the site of onset (limb, bulbar), also
revealed non‑statistically significant results. The respective
results (ORs, CIs, P‑values, mean and standard error of the age
for each genotype) are presented in Table V, for the ALS group
overall. The results from the subgroup analysis regarding
the AAO, based on the site of the ALS onset are presented
in Table VI for the bulbar onset and in Table VII for the limb
onset.
Discussion
The present case‑control study genotyped an ALS cohort
with SEC ancestry aiming to examine the role of the SCFD1
rs10139154 polymorphism in ALS. Based on the results
obtained, the SCFD1 rs10139154 polymorphism was not
associated with ALS. More precisely, the SCFD1 rs10139154
polymorphism neither conferred any susceptibility to ALS
nor influenced the AAO of ALS or its initial manifestation.
Therefore, based on this analysis, it appears rather unlikely
that the SCFD1 rs10139154 polymorphism is among the risk
factors for the development of ALS.
As aforementioned, the SCFD1 is a vesicle‑trafficking
protein, functioning alongside with syntaxins (24,25). The
possible mechanisms via which SCFD1 may be related to ALS
pathophysiology are cellular membrane fusion, oxidative‑stress,
intra‑Golgi‑retrograde transport and apoptosis (23‑26). The
SCFD1 rs10139154 polymorphism is an intronic variant
located at chromosome 14: 30678292 (https://www.ensembl.
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Table II. Allelic and genotype frequencies for SCFD1 rs10139154 in the healthy controls, ALS cases and the whole sample size.
rs10139154 SNP

Genotypes/
alleles

Genotype	C/C	
	C/T
T/T
Missing
Allele 	C	
T

Healthy controls	ALS
(n=155), n (%)
(n=155), n (%)
62 (41)
64 (42)
26 (17)
3
188 (62)
116 (38)

Whole sample
(n=310), n (%)

67 (44)
64 (42)
21 (14)
3
198 (65)
106 (35)

129 (42)
128 (42)
47 (15)
6
386 (63)
222 (37)

SNP, single nucleotide polymorphism; ALS, amyotrophic lateral sclerosis; SCFD1, Sec1 family domain containing 1.

Table III. Single locus analysis (crude and adjusted for age and sex) for association between SCFD1 rs10139154 and ALS, in
co‑dominant, dominant, recessive, overdominant and log‑additive mode.
	Univariate
Mode

‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑

Genotype	OR (95% CI)

Multivariate

‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑

P‑value	OR (95% CI)

Co‑dominant	C/C	
1.00
0.7
	C/T
0.93 (0.57‑1.51)		
T/T
0.75 (0.38‑1.46)		
Dominant	C/C	 1.00
0.56
	C/T‑T/T
0.87 (0.55‑1.38)		
Recessive	C/C‑C/T
1.00
0.43
T/T
0.78 (0.42‑1.45)		
Overdominant	C/C‑T/T
1.00
0.99
	C/T
1.00 (0.63‑1.58)		
Log‑additive
‑
0.88 (0.64‑1.21)
0.42

1.00
0.77 (0.38‑1.54)
0.57 (0.23‑1.39)
1.00
0.70 (0.37‑1.33)
1.00
0.64 (0.28‑1.48)
1.00
0.91 (0.48‑1.73)
0.76 (0.49‑1.16)

P‑value
0.44
0.28
0.3
0.78
0.2

SCFD1, Sec1 family domain containing 1; ALS, amyotrophic lateral sclerosis; CI, confidence interval; OR, odds ratio.

Figure 1. Allele number for SCFD1 rs10139154 in healthy controls and in
ALS cases. HC, healthy controls; ALS, amyotrophic lateral sclerosis; SCFD1,
Sec1 family domain containing 1.

Figure 2. Genotype number for SCFD1 rs10139154 in healthy controls and
in ALS cases. HC, healthy controls; ALS, amyotrophic lateral sclerosis;
SCFD1, Sec1 family domain containing 1.

org/index.html). In a 2016 GWAS on patients with ALS, the
SCFD1 rs10139154 polymorphism was initially reported as
a possibly significant genetic marker (27). More precisely, in
the discovery phase, a statistically significant effect size (OR,
1.09) was reported; whereas the effect size remained at the

replication phase (OR, 1.06) statistical significance was not
achieved.
Additionally, Chen et al (28) reported that the SCFD1
rs10139154 polymorphism was associated with the AAO
of patients with ALS of Chinese ancestry. More precisely,

Genotype	OR (95% CI)

0.25

1.00

1.00

Overdominant	C/C‑T/T

‑

0.91 (0.53‑1.58)

0.75

1.56 (0.72‑3.35)		

0.26

0.50 (0.14‑1.77)		

0.91

0.065

0.21

0.66 (0.29‑1.46)

0.29

1.99 (0.67‑5.90)		

1.00

0.23 (0.04‑1.23)		

1.00

0.94 (0.30‑2.92)		

1.00

0.28 (0.04‑1.72)		

0.16

1.34 (0.40‑4.46)		

1.00

Multivariate

0.26
0.74
0.15

0.89 (0.59‑1.33)

0.56

0.64 (0.34‑1.19)		

1.00

1.14 (0.53‑2.43)		

1.00

0.71 (0.39‑1.28)		

1.00

0.92 (0.41‑2.07)		

0.35

0.80 (0.49‑1.32)

0.59 (0.27‑1.30)

1.00

0.99 (0.39‑2.52)

1.00

0.60 (0.28‑1.29)

1.00

0.74 (0.27‑2.05)

0.54 (0.23‑1.26)

1.00

P‑value	OR (95% CI)

0.63 (0.32‑1.21)		

1.00

P‑value	OR (95% CI)

SCFD1, Sec1 family domain containing 1; ALS, amyotrophic lateral sclerosis; CI, confidence interval; OR, odds ratio.

Log‑additive

	C/T

T/T

1.15 (0.52‑2.52)		

Recessive	C/C‑C/T

	C/T‑T/T

0.73

0.60 (0.16‑2.29)		

1.37 (0.61‑3.11)		

0.39

P‑value	OR (95% CI)

Dominant	C/C	 1.00

T/T

	C/T

Co‑dominant	C/C	 1.00

Mode

‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑

0.38

0.18

0.98

0.19

0.35

P‑value

‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑

‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑

‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑

Multivariate	Univariate

‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑

	Univariate

‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑

Bulbar onset	Limb onset

Table IV. Single locus analysis (crude and adjusted for age and sex) for association between SCFD1 rs10139154 and ALS, based on the site of disease onset (bulbar or limbs), in
co‑dominant, dominant, recessive, overdominant and log‑additive modes.
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Table V. Single locus analysis (crude and adjusted for sex) for association between SCFD1 rs10139154 and AAO of ALS, in
co‑dominant, dominant, recessive, overdominant and log‑additive mode.
	Univariate
Mode
Genotype
Mean (SE)	Difference (95% CI)
P‑value
Co‑dominant	C/C	

	C/T
T/T
Dominant	C/C	
	C/T‑T/T
Recessive	C/C‑C/T
T/T
Overdominant	C/C‑T/T
	C/T
Log‑additive
‑‑‑

63.22 (1.5)

64.75 (1.32)
63.05 (2.44)
63.22 (1.5)
64.33 (1.16)
63.97 (1.00)
63.05 (2.44)
63.18 (1.27)
64.75 (1.32)
‑‑‑

0.00

1.53 (‑2.38 to 5.43)
‑0.18 (‑5.77 to 5.42)
0.00
1.11 (‑2.54 to 4.75)
0.00
‑0.92 (‑6.17 to 4.33)
0.00
1.57 (‑2.09 to 5.23)
0.33 (‑2.26 to 2.93)

Multivariate
P‑value

0.7

0.68

0.55

0.58

0.73

0.67

0.4

0.39

0.8

0.85

SCFD1, Sec1 family domain containing 1; ALS, amyotrophic lateral sclerosis; AAA, age at onset; CI, confidence interval; SE, standard error.

Table VI. Single locus analysis (crude and adjusted for sex) for association between SCFD1 rs10139154 and the AAO of ALS
with bulbar onset, in co‑dominant, dominant, recessive, overdominant and log‑additive mode.
	Univariate
Mode
Genotype
Mean (SE)	Difference (95% CI)
P‑value
Co‑dominant	C/C	
	C/T
T/T
Dominant	C/C	
	C/T‑T/T
Recessive	C/C‑C/T
T/T
Overdominant	C/C‑T/T
	C/T
Log‑additive
‑‑‑

67.83 (2.28)
63.12 (2.81)
66.33 (4.67)
67.83 (2.28)
63.6 (2.46)
65.07 (1.92)
66.33 (4.67)
67.53 (1.98)
63.12 (2.81)
‑‑‑

0.00
‑4.72 (‑12.18 to 2.75)
‑1.50 (‑14.29 to 11.29)
0.00
‑4.23 (‑11.38 to 2.91)
0.00
1.26 (‑10.86 to 13.38)
0.00
‑4.42 (‑11.32 to 2.49)
‑2.27 (‑7.88 to 3.33)

Multivariate
P‑value

0.46

0.51

0.25

0.28

0.84

0.89

0.22

0.25

0.43

0.44

SCFD1, Sec1 family domain containing 1; ALS, amyotrophic lateral sclerosis; AAA, age at onset; CI, confidence interval; SE, standard error.

they found that carriers of the C/C genotype had a lower
AAO of ALS (49.53±10.75 years) compared with the C/T
carriers (53.75±11.84 years; P=0.002). Furthermore, in
the recessive model analysis, C/C carriers had a lower
ALS AAO (49.53±10.75 years) compared with (C/T + T/T;
53.37±11.60 years, P=0.001) (28). Apart from ALS, the SCFD1
rs10139154 ‘T’ allele has been shown to be associated with a
decreased risk of Alzheimer's disease (OR, 0.63; P=0.036), in
the recessive mode (24). However, the aforementioned results
could not be replicated in the present study.
Of note, the minor allele frequency (MAF) at the study
of Chen et al (28) was the ‘C’ allele, while this was found to
be the ‘T’ allele in the present study, suggesting that ancestry
may be important for the discrepancy between the studies.
Based on 1,000 Genomes Project Phase 3 allele frequen‑
cies, there is a great variability at the MAF allele frequency
between populations (https://www.ensembl.org/Homo_
sapiens/Variation/Population?db=core;r=14:30677792‑306787

92;v=rs10139154;vdb=variation;vf=181642009). In fact, while
the ‘C’ allele appears to be the MAF at East Asian and African
population, the ‘T’ allele is considered the MAF at Europeans,
South Asians and Americans.
Apart from genetic variability between ethnicities, there
are other possible explanations for the fact that no asso‑
ciation was found between SCFD1 rs10139154 and ALS.
For instance, the effect of a polymorphism at expression
quantitative trait loci (eQTL); in fact there is evidence to
suggest that variants identified in GWASs may possibly alter
the risk of disease through gene regulation via eQTL (37).
Concerning the rs10139154 polymorphism, it has emerged
as the most significant SCFD1 polymorphism associated
with ALS in a GWAS (27). In addition, for each SCFD1
rs10139154 ‘T’ allele, an increased SCFD1 expression has
been found in different tissue types obtained from geno‑
type‑tissue expression and in post‑mortem control data, as
demonstrated in the study by Iacoangeli et al (38). However,
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Table VII. Single locus analysis (crude and adjusted for sex) for association between SCFD1 rs10139154 and the AAO of ALS
with limb onset, in co‑dominant, dominant, recessive, overdominant and log‑additive mode.
				Univariate
Mode
Genotype
Mean (SE)	Difference (95% CI)
P‑value
Co‑dominant	C/C	
	C/T
T/T
Dominant	C/C	
	C/T‑T/T
Recessive	C/C‑C/T
T/T
Overdominant	C/C‑T/T
	C/T
Log‑additive
‑

61.16 (2.5)
62.6 (2.39)
61.17 (3.61)
61.16 (2.5)
62.06 (1.98)
61.73 (1.77)
61.17 (3.61)
61.16 (2.05)
62.6 (2.39)
‑

0.00
0.92
1.44 (‑5.72 to 8.60)		
0.01 (‑8.48 to 8.49)		
0.00
0.78
0.90 (‑5.34 to 7.14)		
0.00
0.89
‑0.56 (‑8.51 to 7.39)		
0.00
0.68
1.44 (‑5.26 to 8.14)		
0.24 (‑3.82 to 4.29)
0.91

Multivariate
P‑value
0.93
0.8
0.89
0.7
0.92

SCFD1, Sec1 family domain containing 1; ALS, amyotrophic lateral sclerosis; AAA, age at onset; CI, confidence interval; SE, standard error.

no alteration in SCFD1 expression with the addition of the
SCFD1 rs10139154 ‘T’ alleles was found at the post‑mortem
ALS cohort of that study (38). These results suggested that
between the post‑mortem ALS cohort and controls, different
correlations existed between the SCFD1 genotype and
SCFD1 eQTLs expression, which may influence the risk of
the disease (38).
Currently, the available treatments for ALS are very limited,
while patients with ALS usually succumb to the disease within
3‑4 years from the time of diagnosis (39). Therefore, ongoing
trials target precision medicine approaches, and genetic targets
that will possibly influence the natural course of ALS (40).
In this sense, research regarding ALS (with genetic studies
included) may reveal the molecular mechanisms behind
neurodegeneration, and may lead to the development of novel
therapeutic agents (41).
Certain limitations of the present study need to be
mentioned. Firstly, the participants with ALS were not
screened for the commonest fALS genes, namely the
C9orf72, SOD1, TDP‑43 and FUS/TLS genes (10,18). The
authors also acknowledge that another constraint is that in
the current statistical models, several potential cofounders
(genetic and non‑genetic) were not included (15,16). Finally,
the present study had a case‑control design and thus included
all the inherent limitations of such a type of study (42). On
the contrary, it should be noted that a major strength of the
present case‑control study is the homogeneity of the entire
cohort, as the data of both patients with ALS and the control
group were collected from a specific geographical area of
central Greece.
In conclusion, the present study found that the SCFD1
rs10139154 polymorphism was not associated with ALS.
However, whether this genetic locus is among the risk factors
of ALS cannot be established with absolute certitude at the
moment. Bearing in mind the latter considerations, further
large‑scale cooperative studies examining the carriage of the
SCFD1 rs10139154 polymorphism in multiethnic cohorts are
of great necessity, in order for the attribute risk of this variant
to ALS to be fully elucidated.
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